Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans

The latest update is out from Kiniksa Pharmaceuticals ( (KNSA) ).

On June 5, 2025, Kiniksa Pharmaceuticals announced the design and timeline for its Phase 2/3 clinical trial of KPL-387, a monoclonal antibody for treating recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. This trial aims to evaluate the efficacy and safety of KPL-387, which is administered subcutaneously, and could potentially expand treatment options for patients with recurrent pericarditis. The announcement underscores Kiniksa’s commitment to advancing its therapeutic options and strengthening its position in the cardiovascular treatment market.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Spark’s Take on KNSA Stock

According to Spark, TipRanks’ AI Analyst, KNSA is a Outperform.

Kiniksa Pharmaceuticals presents a strong growth narrative with improving financial performance and a positive earnings outlook. However, the negative P/E ratio and technical indicators suggest caution. The company’s strategic initiatives and positive earnings call sentiment contribute to an encouraging outlook, but past financial instability and valuation concerns weigh on the score.

To see Spark’s full report on KNSA stock, click here.

More about Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with unmet needs, particularly in cardiovascular indications. The company’s portfolio is based on strong biologic rationale or validated mechanisms, offering potential differentiation in the market.

Average Trading Volume: 618,173

Technical Sentiment Signal: Buy

Current Market Cap: $2.12B

Learn more about KNSA stock on TipRanks’ Stock Analysis page.